EGFR and non-small cell lung carcinoma: The aim of the present study was to characterize the real-world diagnostic-therapeutic pathway and clinical outcomes of early-stage NSCLC, with particular reference to the EGFR-mutant subgroup, at a reference thoracic oncology unit in the Veneto Region.